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DESCRIPTION
A previously healthy 57-year-old man presented with
epistaxis, crusted nasal ulcers and weight loss. CT
scan of the sinuses revealed an inﬂammatory swelling
of the ethmoid and maxillary sinuses (ﬁgure 1) and
CTscan of the lungs showed two pulmonary nodular
lesions in both upper lobes. Laboratory investigation
showed an elevated erythrocyte sedimentation rate
(97 mm/h) and a positive anti-PR3-antineutrophil
cytoplasmic antibody.
The diagnosis of Wegener’s granulomatosis (WG)
was made and the patient was started on immuno-
suppression with cyclophosphamide and glucocorti-
coids followed by maintenance therapy with
azathioprine, with subsequent disease remission.
After 2 years, the disease relapsed with haemop-
tysis and external popliteal sciatic mononeuropathy.
A thoracic CT scan revealed multiple pulmonary
nodular lesions and ground-glass inﬁltrate of the
right lower lobe, compatible with alveolar haemor-
rhage (ﬁgure 2). The patient started treatment with
rituximab with completely resolution of the symp-
toms and pulmonary lesions. He remained asymp-
tomatic at 2-year follow-up.
WG is a primary systemic vasculitis, with predi-
lection for the respiratory tract and kidney involve-
ment. Although pulmonary ﬁndings are common,
diffuse alveolar haemorrhage is a rare and life-
threatening manifestation of WG. It is associated
with six times greater mortality than vasculitis
without pulmonary haemorrhage.1
Cyclophosphamide is still the standard induction
therapy for patients with WG. Nevertheless, relapse
is common in up to 50% of patients and rituximab
has been proving to be an effective remission indu-
cing agent in severe refractory WG.1 2
Learning points
▸ Despite the poor outcome of patients with
alveolar haemorrhage, it can have a benign
course with prompt immunosuppression.
▸ Rituximab is an effective immunosuppressive
therapy for the induction and maintenance of
remission in refractory Wegener’s granulomatosis.
▸ As most patients with antineutrophil
cytoplasmic antibody associated-vasculitis
relapse, a close monitoring of the patients is
crucial for an early diagnosis and therapeutics.
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Figure 1 CT scan of the sinuses showing an
inﬂammatory swelling of the ethmoid and maxillary
sinuses (arrow).
Figure 2 Thoracic CT scan showing pulmonary nodular
lesions and alveolar haemorrhage in the right lower lobe.
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